Candiolo

• A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti_Tumor Activity of AVZO-02 … Pending
  2024-517339-30-00 7 Advanced Solid Tumors
• Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus RAdiotherapy in Soft Tissue Sarcoma pat … Pending
  2024-518199-30-00 9 Soft tissue sarcoma patients
• A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm … Pending
  2024-519087-41-00 5 Breast cancer is the most common form of cancer among women in North A
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending
  2024-519504-27-00 5 Relapsed Refractory Multiple Myeloma
• Phase II, clinical trial, to evaluate OS in two cohorts in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiot … Pending
  2024-520081-65-00 4 NSCLC non-small cell lung cancer
• A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in … Pending
  2025-521000-22-00 3 Patients with advanced malignancies
• A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer Pending
  2025-521001-40-00 3 Advanced Malignancies and Hepatic Impairment
• TALIM study, for the treatment of patients affected by persisent or recurrent Multiple Myeloma with the drug teclistamab and infusions of ly … Pending
  2025-521827-61-00 4 refractory/relapsed multiple myeloma
• A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 Pending
  2025-522084-15-00 10 metastatic NSCLC patients
• A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma Pending
  2025-522523-96-00 1 T-cell Non-Hodgkin Lymphoma
• A clinical study of MK-1045 in people with non-Hodgkin lymphoma (MK-1045-008) Pending
  2025-523005-15-00 9 Non-Hodgkin Lymphoma
• Symbiotic-GI-13, A Study to Learn About the Study Medicine Called PF-08634404 as Monotherapy and Combination Therapy in Adult Participants w … Pending
  2025-523525-17-00 9 Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
• A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-naïve adults who require RBC … Pending
  2025-523544-12-00 5 Myelodysplastic neoplasms/syndromes (MDS)
• A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending
  2025-523586-18-00 5 Non-Small Cell Lung Cancer
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer Recruiting
  2025-522107-18-00 4 2026-05-19 Locally advanced or metastatic Non-Small Cell Lung Cancer
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be … Recruiting
  2024-510778-26-00 4 2025-12-19 Metastatic Non-Small-Cell Lung Cancer
• A Phase 3 Study of DZD8586 versus Investigator’s Choice in r/r CLL/SLL Recruiting
  2025-522669-32-00 5 2025-12-18 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 5 2025-11-12 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
• A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a … Recruiting
  2023-505172-29-00 4 2025-04-24 Resectable Non-small Cell Lung Cancer
• A study to investigate efficacy and safety of INT230-6 compared with US standard of care in participants aged ≥ 18 years old with metastatic … Recruiting
  2024-512423-36-00 5 2024-11-20 Undifferentiated pleomorphic sarcoma
• A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Teno … Recruiting
  2023-510422-32-00 5 2024-09-10 Tenosynovial Giant Cell Tumour

Showing 1–24 of 184 trials